Completed PHASE1 INTERVENTIONAL 2-arm NCT05168683

Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets

A Phase 1, Single Centre, Two-Part, Open Label, Crossover Study in Healthy Volunteers Using Scintigraphy to Characterize the In Vivo Performance of ALLN-346 Enteric Coated Tablets

Sponsor: Allena Pharmaceuticals

Conditions Gout Hyperuricemia

Interventions Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal

Updated 6 times since 2022 Last updated: Jan 20, 2023 Started: Jan 11, 2022 Primary completion: Feb 23, 2022 Completion: Feb 23, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Gout and Hyperuricemia, this trial is completed. The trial is conducted by Allena Pharmaceuticals and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE1
Mar 2022 — Sep 2022 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allena Pharmaceuticals
BDD Pharma Ltd

Data source: Allena Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Glasgow, United Kingdom